[Effect of disorders of thyroid function on phenazone pharmacokinetics].
Phenazone elimination test, as a marker of metabolic efficiency of the liver, was carried out in 11 hypothyroid patients. 20 hyperthyroid patients, 10 persons after hyperthyroidism treatment and in 20 healthy persons as a control group. In hyperthyroid patients the acceleration, and in hypothyroid patients the delay of phenazone elimination, in comparison with a control group was observed. Moreover, the impairment of phenazone gastrointestinal absorption was shown in hypothyroid patients and in persons after hyperthyroidism treatment. Similar alterations may be expected in persons with thyroid dysfunctions to whom the drugs with pharmacokinetic properties similar to phenazone are administered.
Bolanowski
M
M
Katedry i Zakładu Farmakologii Klinicznej.
Orzechowska-Juzwenko
K
K
Gruszka
S
S
Szymczak
J
J
D000328:Adult; D000983:Antipyrine / Q000493:pharmacokinetics*; D001711:Biotransformation / Q000502:physiology; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000378:metabolism*; D007037:Hypothyroidism / Q000378:metabolism*; D008111:Liver Function Tests; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism*; D008875:Middle Aged; D013997:Time Factors
D000983:Antipyrine
Wpływ zaburzonej czynności tarczycy na farmakokinetyke fenazonu.